Literature DB >> 16540234

Haplotypic structure across the I kappa B alpha gene (NFKBIA) and association with multiple myeloma.

Charlotte F Spink1, Lisa C Gray, Faith E Davies, Gareth J Morgan, Jeffrey L Bidwell.   

Abstract

Polymorphisms in NFKBIA may be important in pre-disposition to and outcome after treatment, of multiple myeloma (MM). The NFKBIA gene product, IkappaBalpha, binds to NF-kappaB preventing its activation and is important in mediating resistance to apoptosis in B-cell lymphoproliferative diseases. This study investigates eight polymorphisms across the NFKBIA gene in large patient and control populations. Significant differences in the frequency of particular polymorphisms were noted between patients and controls. A risk haplotype [GCCTATCA] for MM was also identified (P=0.006). Analysis of the genetics of NFKBIA may lead to associations with disease progression and survival and thus more personalized therapy.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16540234     DOI: 10.1016/j.canlet.2006.02.001

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  16 in total

1.  NFKBIA deletion in glioblastomas.

Authors:  Markus Bredel; Denise M Scholtens; Ajay K Yadav; Angel A Alvarez; Jaclyn J Renfrow; James P Chandler; Irene L Y Yu; Maria S Carro; Fangping Dai; Michael J Tagge; Roberto Ferrarese; Claudia Bredel; Heidi S Phillips; Paul J Lukac; Pierre A Robe; Astrid Weyerbrock; Hannes Vogel; Steven Dubner; Bret Mobley; Xiaolin He; Adrienne C Scheck; Branimir I Sikic; Kenneth D Aldape; Arnab Chakravarti; Griffith R Harsh
Journal:  N Engl J Med       Date:  2010-12-22       Impact factor: 91.245

Review 2.  Inherited genetic susceptibility to multiple myeloma.

Authors:  G J Morgan; D C Johnson; N Weinhold; H Goldschmidt; O Landgren; H T Lynch; K Hemminki; R S Houlston
Journal:  Leukemia       Date:  2013-11-19       Impact factor: 11.528

3.  Polymorphisms of nuclear factor-κB family genes are associated with development of multiple myeloma and treatment outcome in patients receiving bortezomib-based regimens.

Authors:  Juan Du; Jun Huo; Jun Shi; Zhengang Yuan; Chunyang Zhang; Weijun Fu; Hua Jiang; Qing Yi; Jian Hou
Journal:  Haematologica       Date:  2011-01-12       Impact factor: 9.941

4.  IkappaBalpha polymorphism at promoter region (rs2233408) influences the susceptibility of gastric cancer in Chinese.

Authors:  Shiyan Wang; Linwei Tian; Zhirong Zeng; Mingdong Zhang; Kaichun Wu; Minhu Chen; Daiming Fan; Pinjin Hu; Joseph J Y Sung; Jun Yu
Journal:  BMC Gastroenterol       Date:  2010-02-05       Impact factor: 3.067

5.  Polymorphic variation in NFKB1 and other aspirin-related genes and risk of Hodgkin lymphoma.

Authors:  Ellen T Chang; Brenda M Birmann; Julie L Kasperzyk; David V Conti; Peter Kraft; Richard F Ambinder; Tongzhang Zheng; Nancy E Mueller
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2009-02-17       Impact factor: 4.254

6.  DLC1 tumor suppressor gene inhibits migration and invasion of multiple myeloma cells through RhoA GTPase pathway.

Authors:  V Ullmannova-Benson; M Guan; X Zhou; V Tripathi; X-Y Yang; D B Zimonjic; N C Popescu
Journal:  Leukemia       Date:  2008-10-16       Impact factor: 11.528

7.  Effects of NFKB1 and NFKBIA gene polymorphisms on susceptibility to environmental factors and the clinicopathologic development of oral cancer.

Authors:  Chiao-Wen Lin; Yih-Shou Hsieh; Chung-Han Hsin; Chun-Wen Su; Chien-Huang Lin; Lin-Hung Wei; Shun-Fa Yang; Ming-Hsien Chien
Journal:  PLoS One       Date:  2012-04-11       Impact factor: 3.240

8.  MiR-196a promotes pancreatic cancer progression by targeting nuclear factor kappa-B-inhibitor alpha.

Authors:  Fengting Huang; Jian Tang; Xiaohong Zhuang; Yanyan Zhuang; Wenjie Cheng; Wenbo Chen; Herui Yao; Shineng Zhang
Journal:  PLoS One       Date:  2014-02-04       Impact factor: 3.240

9.  IkappaBalpha gene promoter polymorphisms are associated with hepatocarcinogenesis in patients infected with hepatitis B virus genotype C.

Authors:  Yongchao He; Hongwei Zhang; Jianhua Yin; Jiaxin Xie; Xiaojie Tan; Shijian Liu; Qian Zhang; Chengzhong Li; Jun Zhao; Hongyang Wang; Guangwen Cao
Journal:  Carcinogenesis       Date:  2009-10-01       Impact factor: 4.944

10.  Polymorphisms in NF-kappaB inhibitors and risk of epithelial ovarian cancer.

Authors:  Kristin L White; Robert A Vierkant; Catherine M Phelan; Brooke L Fridley; Stephanie Anderson; Keith L Knutson; Joellen M Schildkraut; Julie M Cunningham; Linda E Kelemen; V Shane Pankratz; David N Rider; Mark Liebow; Lynn C Hartmann; Thomas A Sellers; Ellen L Goode
Journal:  BMC Cancer       Date:  2009-06-06       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.